TCGA-05-4389-01A-01R-1206-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.440
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.400
- OXIDATIVE_PHOSPHORYLATION+0.380
- BILE_ACID_METABOLISM+0.370
- FATTY_ACID_METABOLISM+0.370
- XENOBIOTIC_METABOLISM+0.370
- PEROXISOME+0.350
- INTERFERON_ALPHA_RESPONSE+0.320
- INTERFERON_GAMMA_RESPONSE+0.300
- PANCREAS_BETA_CELLS+0.260
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- UV_RESPONSE_DN-0.390
- TGF_BETA_SIGNALING-0.360
- HYPOXIA-0.350
- MITOTIC_SPINDLE-0.340
- TNFA_SIGNALING_VIA_NFKB-0.340
- HEDGEHOG_SIGNALING-0.310
- APICAL_SURFACE-0.290
- G2M_CHECKPOINT-0.290
- ANGIOGENESIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208921 | — | — | 0.815 |
| 2 | TCGA-05-5420-01A-01R-1628-07 | — | cohortA1 | 0.797 |
| 3 | SRR8518342 | — | F | 0.775 |
| 4 | AUR-AFUK-TTM1-A-1-0-R-A743-41 | — | B | 0.773 |
| 5 | 45a2676b-25ba-41b0-9e55-08c6eb3a8f2f | — | — | 0.772 |
| 6 | ec4f2c9f.7d4b.45fe.9064.f96e4a1e52e6 | — | cohortA4 | 0.761 |
| 7 | TCGA-E2-A1IK-01A-11R-A144-07 | — | B | 0.760 |
| 8 | TCGA-05-4422-01A-01R-1206-07 | — | cohortA3 | 0.756 |
| 9 | SRR4296112 | — | cohortA1 | 0.753 |
| 10 | a8cd01e2-f7f4-487c-8cde-4fcf21bfe0e7 | — | — | 0.751 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.370 | Inavolisib | — uncovered |
| PEROXISOME | 0.350 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.320 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.210 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |